UK – Mylan & Ors. v. Yeda

Posted: November 7th, 2017

Generics (UK) Limited trading as Mylan & Ors. v Yeda Research and Development Company Limited & Ors, High Court, London, UK, 26 October 2017, Neutral Citation Number: [2017] EWHC 2692 (Pat) This case was brought by the Claimants (Mylan and Synthon) seeking revocation of EP (UK) 2,949,335 (“EP’335”), a patent owned by Yeda and exclusively […]


UK – MSD v. Shionogi

Posted: December 21st, 2016

Merck Sharp and Dohme Limited v Shionogi & Co. Limited, High Court of England and Wales (Arnold J), 25 November 2015, Neutral Citation Number [2016] EWHC 2989 (Pat) The claimant, Merck, sought revocation of Shionogi’s EP(UK) 1 422 218. The defendant, Shionogi, counterclaimed for infringement by Merck’s integrase inhibitor raltegravir, marketed as Isentress. Shionogi made […]


UK – Gilead v. Idenix

Posted: November 21st, 2016

Idenix Pharmaceuticals Inc. v. Gilead Sciences Inc., Court of Appeal, London, UK, 8 November 2016, Case no. [2016] EWCA Civ 1089 The Court of Appeal has upheld Arnold J’s judgment on the Gilead v Idenix case, which concerned the validity of Idenix’s patent EP(UK)1 523 489 covering a family of nucleoside analogues for the treatment […]


UK – Warner-Lambert v. Actavis

Posted: October 17th, 2016

Warner-Lambert Company LLC v (1) Generics (UK) Limited (trading as Mylan), (2) Actavis Group PTC EHF, (3) Actavis UK Limited and (4) Caduceus Pharma Limited, England and Wales Court of Appeal (Floyd, Pattern and Kitchin LJJ), London UK, 13 October 2016, Neutral Citation Number: [2016] EWCA Civ 1006 The Court of Appeal dismissed Warner-Lambert’s appeal […]


NO – Idenix v. Gilead

Posted: July 21st, 2016

Idenix Pharmaceuticals, Inc. together with Centre National de la Recherche Scientifique, Università degli Studi di Cagliari and L’Université Montpellier II were the proprietors of Norwegian patent NO 330 755. The patent was directed to certain nucleoside analogues with anti-viral activity. Amongst the compounds covered by NO 330 755 was sofosbuvir which is the active ingredient […]


UK – GlaxoSmithKline v Wyeth Holdings

Posted: May 20th, 2016

GlaxoSmithKline UK Limited v Wyeth Holdings LLC, High Court of Justice of England & Wales (Patents Court), London, UK, Carr J, 12 May 2016, Neutral Citation Number: [2016] EWHC 1045 (CH) Carr J has upheld the validity of Wyeth’s patent EP(UK) 2,343,308 relating to a combination product comprising a 2086 protein and a PorA protein […]


NL – Ajinomoto v. Global Bio-Chem

Posted: May 3rd, 2016

Ajinomoto Co. Inc. and Ajinomoto Eurolysine A.S. v. Global Bio-Chem Technology Group Company Limited et al., Court of Appeal the Hague, the Netherlands, 26 April 2016, Case No. 200-161.842/01 Ajinomoto appealed the judgment in which the District Court (in the counterclaim) invalidated Ajinomoto’s patent EP 1664318 relating to the the production of L-lysine and in […]


UK – Regeneron v. Kymab and Novo Nordisk

Posted: February 16th, 2016

Regeneron Pharmaceuticals Inc v Kymab Limited and Novo Nordisk A/S, High Court of England and Wales (Carr J), London, UK, 1 February 2016, Neutral Citation Number: [2016] EWHC 87 (Pat).  On 3 February 2016 the Patents Court (Carr J) held that the disputed claims of two of Regeneron’s patents relating to transgenic mice used for […]


UK – Actavis v. Eli Lilly

Posted: December 7th, 2015

Actavis Group PTC EHF & Anor v Eli Lilly and Company, High Court of England and Wales (Carr J), London, UK, 16 November 2015, Neutral Citation Number: [2015] EWHC 3294 (Pat) This was an action by Actavis to “clear the way” in relation to atomoxetine, the first non-stimulant to be approved for the treatment of […]